Global PSMA Imaging Agent for Prostate Cancer Market Growth 2026-2032
The global PSMA Imaging Agent for Prostate Cancer market size is predicted to grow from US$ 1731 million in 2025 to US$ 2839 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.
In 2025, the global production of PSMA imaging agent for prostate cancer reached 3.5394 million units, with an average selling price of $500 per unit. The annual production capacity of PSMA imaging agents for prostate cancer worldwide is approximately 5 million units, with a gross margin of about 30.4%. PSMA imaging agent for prostate cancer is a radiotracer that targets prostate?specific membrane antigen (PSMA) and enables molecular?level imaging of prostate cancer lesions via positron emission tomography (PET). PSMA is highly expressed on the surface of prostate cancer cells. After the imaging agent specifically binds to it, PET/CT or PET/MRI equipment is used to detect radioactive signals, thereby enabling high?sensitivity localization of primary lesions, detection of metastases, and assessment of recurrence. It is currently an important tool in precision diagnosis and treatment of prostate cancer. The upstream of PSMA imaging agents for prostate cancer includes radionuclides (such as gallium?68, fluorine?18, etc.), PSMA?targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators, among others. The midstream consists of manufacturers of PSMA imaging agents for prostate cancer, while the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnosis, and radiopharmaceuticals and nuclear medicine.
Currently, the market for PSMA imaging agent for prostate cancer is in a phase of rapid development. As a revolutionary molecular imaging tool, it has been widely integrated into clinical management pathways for prostate cancer, playing a key role especially in initial staging, detection of biochemical recurrence, and formulation of treatment strategies. With the growing availability of PET/CT and PET/MRI equipment and the continuous emergence of novel PSMA ligands, the clinical applications of this imaging agent are steadily expanding. Meanwhile, the rise of the theranostics concept means that PSMA imaging agents for prostate cancer are not only used for diagnosis but are also beginning to be linked with PSMA?targeted radionuclide therapy, ushering prostate cancer into a new era of precision medicine. Furthermore, improvements in regulatory approval and standardized production requirements for radiopharmaceuticals, along with gradual optimization of reimbursement policies, have further contributed to the maturation and growth of this market.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “PSMA Imaging Agent for Prostate Cancer Industry Forecast” looks at past sales and reviews total world PSMA Imaging Agent for Prostate Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected PSMA Imaging Agent for Prostate Cancer sales for 2026 through 2032. With PSMA Imaging Agent for Prostate Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PSMA Imaging Agent for Prostate Cancer industry.
This Insight Report provides a comprehensive analysis of the global PSMA Imaging Agent for Prostate Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PSMA Imaging Agent for Prostate Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PSMA Imaging Agent for Prostate Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PSMA Imaging Agent for Prostate Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PSMA Imaging Agent for Prostate Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of PSMA Imaging Agent for Prostate Cancer market by product type, application, key manufacturers and key regions and countries.
In 2025, the global production of PSMA imaging agent for prostate cancer reached 3.5394 million units, with an average selling price of $500 per unit. The annual production capacity of PSMA imaging agents for prostate cancer worldwide is approximately 5 million units, with a gross margin of about 30.4%. PSMA imaging agent for prostate cancer is a radiotracer that targets prostate?specific membrane antigen (PSMA) and enables molecular?level imaging of prostate cancer lesions via positron emission tomography (PET). PSMA is highly expressed on the surface of prostate cancer cells. After the imaging agent specifically binds to it, PET/CT or PET/MRI equipment is used to detect radioactive signals, thereby enabling high?sensitivity localization of primary lesions, detection of metastases, and assessment of recurrence. It is currently an important tool in precision diagnosis and treatment of prostate cancer. The upstream of PSMA imaging agents for prostate cancer includes radionuclides (such as gallium?68, fluorine?18, etc.), PSMA?targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators, among others. The midstream consists of manufacturers of PSMA imaging agents for prostate cancer, while the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnosis, and radiopharmaceuticals and nuclear medicine.
Currently, the market for PSMA imaging agent for prostate cancer is in a phase of rapid development. As a revolutionary molecular imaging tool, it has been widely integrated into clinical management pathways for prostate cancer, playing a key role especially in initial staging, detection of biochemical recurrence, and formulation of treatment strategies. With the growing availability of PET/CT and PET/MRI equipment and the continuous emergence of novel PSMA ligands, the clinical applications of this imaging agent are steadily expanding. Meanwhile, the rise of the theranostics concept means that PSMA imaging agents for prostate cancer are not only used for diagnosis but are also beginning to be linked with PSMA?targeted radionuclide therapy, ushering prostate cancer into a new era of precision medicine. Furthermore, improvements in regulatory approval and standardized production requirements for radiopharmaceuticals, along with gradual optimization of reimbursement policies, have further contributed to the maturation and growth of this market.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “PSMA Imaging Agent for Prostate Cancer Industry Forecast” looks at past sales and reviews total world PSMA Imaging Agent for Prostate Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected PSMA Imaging Agent for Prostate Cancer sales for 2026 through 2032. With PSMA Imaging Agent for Prostate Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PSMA Imaging Agent for Prostate Cancer industry.
This Insight Report provides a comprehensive analysis of the global PSMA Imaging Agent for Prostate Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PSMA Imaging Agent for Prostate Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PSMA Imaging Agent for Prostate Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PSMA Imaging Agent for Prostate Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PSMA Imaging Agent for Prostate Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of PSMA Imaging Agent for Prostate Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 68Ga
- 18F
Segmentation by Core Carrier Materials:
- First Generation
- Second Generation
Segmentation by Mechanism of Action:
- Active Targeting
- Passive Targeting
Segmentation by Application:
- Nuclear Medicine and Molecular Imaging
- Precision Oncology Diagnostics
- Radiopharmaceuticals and Radiopharmaceuticals
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lantheus
- Telix Pharmaceuticals
- Novartis
- Blue Earth Diagnostics?Bracco?
- Sinotau
- DC PHARMA
- Clarity Pharmaceuticals
- Hengrui Pharma
- CRAND PHARMACEUTICAL
- Norroy Bioscience
- HUAYI RADIOPHARMACEUTICALS
- Yunhe Pharma
- C Ray Therapeutics
- Curium Holding France S.A.S.
- ABX advanced biochemical compounds GmbH
- Isotopia Molecular Imaging Ltd.
Key Questions Addressed in this Report
- What is the 10-year outlook for the global PSMA Imaging Agent for Prostate Cancer market?
- What factors are driving PSMA Imaging Agent for Prostate Cancer market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do PSMA Imaging Agent for Prostate Cancer market opportunities vary by end market size?
- How does PSMA Imaging Agent for Prostate Cancer break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PSMA Imaging Agent for Prostate Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PSMA Imaging Agent for Prostate Cancer by Country/Region, 2021, 2025 & 2032
2.2 PSMA Imaging Agent for Prostate Cancer Segment by Type
2.2.1 68Ga
2.2.2 18F
2.2.3 PSMA Imaging Agent for Prostate Cancer Sales by Type
2.2.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
2.2.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Type (2021-2026)
2.3 PSMA Imaging Agent for Prostate Cancer Segment by Core Carrier Materials
2.3.1 First Generation
2.3.2 Second Generation
2.3.3 PSMA Imaging Agent for Prostate Cancer Sales by Core Carrier Materials
2.3.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials (2021-2026)
2.3.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Core Carrier Materials (2021-2026)
2.3.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Core Carrier Materials (2021-2026)
2.4 PSMA Imaging Agent for Prostate Cancer Segment by Mechanism of Action
2.4.1 Active Targeting
2.4.2 Passive Targeting
2.4.3 PSMA Imaging Agent for Prostate Cancer Sales by Mechanism of Action
2.4.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action (2021-2026)
2.4.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Mechanism of Action (2021-2026)
2.4.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Mechanism of Action (2021-2026)
2.5 PSMA Imaging Agent for Prostate Cancer Segment by Application
2.5.1 Nuclear Medicine and Molecular Imaging
2.5.2 Precision Oncology Diagnostics
2.5.3 Radiopharmaceuticals and Radiopharmaceuticals
2.5.4 PSMA Imaging Agent for Prostate Cancer Sales by Application
2.5.4.1 Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2021-2026)
2.5.4.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PSMA Imaging Agent for Prostate Cancer Breakdown Data by Company
3.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Company (2021-2026)
3.1.2 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company (2021-2026)
3.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global PSMA Imaging Agent for Prostate Cancer Revenue by Company (2021-2026)
3.2.2 Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company (2021-2026)
3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Company
3.4 Key Manufacturers PSMA Imaging Agent for Prostate Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PSMA Imaging Agent for Prostate Cancer Product Location Distribution
3.4.2 Players PSMA Imaging Agent for Prostate Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSMA IMAGING AGENT FOR PROSTATE CANCER BY GEOGRAPHIC REGION
4.1 World Historic PSMA Imaging Agent for Prostate Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PSMA Imaging Agent for Prostate Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas PSMA Imaging Agent for Prostate Cancer Sales Growth
4.4 APAC PSMA Imaging Agent for Prostate Cancer Sales Growth
4.5 Europe PSMA Imaging Agent for Prostate Cancer Sales Growth
4.6 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Growth
5 AMERICAS
5.1 Americas PSMA Imaging Agent for Prostate Cancer Sales by Country
5.1.1 Americas PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
5.1.2 Americas PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
5.2 Americas PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
5.3 Americas PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PSMA Imaging Agent for Prostate Cancer Sales by Region
6.1.1 APAC PSMA Imaging Agent for Prostate Cancer Sales by Region (2021-2026)
6.1.2 APAC PSMA Imaging Agent for Prostate Cancer Revenue by Region (2021-2026)
6.2 APAC PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
6.3 APAC PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PSMA Imaging Agent for Prostate Cancer by Country
7.1.1 Europe PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
7.1.2 Europe PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
7.2 Europe PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
7.3 Europe PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer by Country
8.1.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
8.3 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PSMA Imaging Agent for Prostate Cancer
10.3 Manufacturing Process Analysis of PSMA Imaging Agent for Prostate Cancer
10.4 Industry Chain Structure of PSMA Imaging Agent for Prostate Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PSMA Imaging Agent for Prostate Cancer Distributors
11.3 PSMA Imaging Agent for Prostate Cancer Customer
12 WORLD FORECAST REVIEW FOR PSMA IMAGING AGENT FOR PROSTATE CANCER BY GEOGRAPHIC REGION
12.1 Global PSMA Imaging Agent for Prostate Cancer Market Size Forecast by Region
12.1.1 Global PSMA Imaging Agent for Prostate Cancer Forecast by Region (2027-2032)
12.1.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PSMA Imaging Agent for Prostate Cancer Forecast by Type (2027-2032)
12.7 Global PSMA Imaging Agent for Prostate Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus
13.1.1 Lantheus Company Information
13.1.2 Lantheus PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.1.3 Lantheus PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Main Business Overview
13.1.5 Lantheus Latest Developments
13.2 Telix Pharmaceuticals
13.2.1 Telix Pharmaceuticals Company Information
13.2.2 Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.2.3 Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Telix Pharmaceuticals Main Business Overview
13.2.5 Telix Pharmaceuticals Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.3.3 Novartis PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Blue Earth Diagnostics?Bracco?
13.4.1 Blue Earth Diagnostics?Bracco? Company Information
13.4.2 Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics?Bracco? Main Business Overview
13.4.5 Blue Earth Diagnostics?Bracco? Latest Developments
13.5 Sinotau
13.5.1 Sinotau Company Information
13.5.2 Sinotau PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.5.3 Sinotau PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinotau Main Business Overview
13.5.5 Sinotau Latest Developments
13.6 DC PHARMA
13.6.1 DC PHARMA Company Information
13.6.2 DC PHARMA PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.6.3 DC PHARMA PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 DC PHARMA Main Business Overview
13.6.5 DC PHARMA Latest Developments
13.7 Clarity Pharmaceuticals
13.7.1 Clarity Pharmaceuticals Company Information
13.7.2 Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.7.3 Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Clarity Pharmaceuticals Main Business Overview
13.7.5 Clarity Pharmaceuticals Latest Developments
13.8 Hengrui Pharma
13.8.1 Hengrui Pharma Company Information
13.8.2 Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.8.3 Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hengrui Pharma Main Business Overview
13.8.5 Hengrui Pharma Latest Developments
13.9 CRAND PHARMACEUTICAL
13.9.1 CRAND PHARMACEUTICAL Company Information
13.9.2 CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.9.3 CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CRAND PHARMACEUTICAL Main Business Overview
13.9.5 CRAND PHARMACEUTICAL Latest Developments
13.10 Norroy Bioscience
13.10.1 Norroy Bioscience Company Information
13.10.2 Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.10.3 Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Norroy Bioscience Main Business Overview
13.10.5 Norroy Bioscience Latest Developments
13.11 HUAYI RADIOPHARMACEUTICALS
13.11.1 HUAYI RADIOPHARMACEUTICALS Company Information
13.11.2 HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.11.3 HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 HUAYI RADIOPHARMACEUTICALS Main Business Overview
13.11.5 HUAYI RADIOPHARMACEUTICALS Latest Developments
13.12 Yunhe Pharma
13.12.1 Yunhe Pharma Company Information
13.12.2 Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.12.3 Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Yunhe Pharma Main Business Overview
13.12.5 Yunhe Pharma Latest Developments
13.13 C Ray Therapeutics
13.13.1 C Ray Therapeutics Company Information
13.13.2 C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.13.3 C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 C Ray Therapeutics Main Business Overview
13.13.5 C Ray Therapeutics Latest Developments
13.14 Curium Holding France S.A.S.
13.14.1 Curium Holding France S.A.S. Company Information
13.14.2 Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.14.3 Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Curium Holding France S.A.S. Main Business Overview
13.14.5 Curium Holding France S.A.S. Latest Developments
13.15 ABX advanced biochemical compounds GmbH
13.15.1 ABX advanced biochemical compounds GmbH Company Information
13.15.2 ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.15.3 ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 ABX advanced biochemical compounds GmbH Main Business Overview
13.15.5 ABX advanced biochemical compounds GmbH Latest Developments
13.16 Isotopia Molecular Imaging Ltd.
13.16.1 Isotopia Molecular Imaging Ltd. Company Information
13.16.2 Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.16.3 Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Isotopia Molecular Imaging Ltd. Main Business Overview
13.16.5 Isotopia Molecular Imaging Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PSMA Imaging Agent for Prostate Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PSMA Imaging Agent for Prostate Cancer by Country/Region, 2021, 2025 & 2032
2.2 PSMA Imaging Agent for Prostate Cancer Segment by Type
2.2.1 68Ga
2.2.2 18F
2.2.3 PSMA Imaging Agent for Prostate Cancer Sales by Type
2.2.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
2.2.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Type (2021-2026)
2.3 PSMA Imaging Agent for Prostate Cancer Segment by Core Carrier Materials
2.3.1 First Generation
2.3.2 Second Generation
2.3.3 PSMA Imaging Agent for Prostate Cancer Sales by Core Carrier Materials
2.3.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials (2021-2026)
2.3.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Core Carrier Materials (2021-2026)
2.3.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Core Carrier Materials (2021-2026)
2.4 PSMA Imaging Agent for Prostate Cancer Segment by Mechanism of Action
2.4.1 Active Targeting
2.4.2 Passive Targeting
2.4.3 PSMA Imaging Agent for Prostate Cancer Sales by Mechanism of Action
2.4.3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action (2021-2026)
2.4.3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Mechanism of Action (2021-2026)
2.4.3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Mechanism of Action (2021-2026)
2.5 PSMA Imaging Agent for Prostate Cancer Segment by Application
2.5.1 Nuclear Medicine and Molecular Imaging
2.5.2 Precision Oncology Diagnostics
2.5.3 Radiopharmaceuticals and Radiopharmaceuticals
2.5.4 PSMA Imaging Agent for Prostate Cancer Sales by Application
2.5.4.1 Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2021-2026)
2.5.4.2 Global PSMA Imaging Agent for Prostate Cancer Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PSMA Imaging Agent for Prostate Cancer Breakdown Data by Company
3.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Company (2021-2026)
3.1.2 Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company (2021-2026)
3.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global PSMA Imaging Agent for Prostate Cancer Revenue by Company (2021-2026)
3.2.2 Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company (2021-2026)
3.3 Global PSMA Imaging Agent for Prostate Cancer Sale Price by Company
3.4 Key Manufacturers PSMA Imaging Agent for Prostate Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PSMA Imaging Agent for Prostate Cancer Product Location Distribution
3.4.2 Players PSMA Imaging Agent for Prostate Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSMA IMAGING AGENT FOR PROSTATE CANCER BY GEOGRAPHIC REGION
4.1 World Historic PSMA Imaging Agent for Prostate Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PSMA Imaging Agent for Prostate Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global PSMA Imaging Agent for Prostate Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas PSMA Imaging Agent for Prostate Cancer Sales Growth
4.4 APAC PSMA Imaging Agent for Prostate Cancer Sales Growth
4.5 Europe PSMA Imaging Agent for Prostate Cancer Sales Growth
4.6 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Growth
5 AMERICAS
5.1 Americas PSMA Imaging Agent for Prostate Cancer Sales by Country
5.1.1 Americas PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
5.1.2 Americas PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
5.2 Americas PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
5.3 Americas PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PSMA Imaging Agent for Prostate Cancer Sales by Region
6.1.1 APAC PSMA Imaging Agent for Prostate Cancer Sales by Region (2021-2026)
6.1.2 APAC PSMA Imaging Agent for Prostate Cancer Revenue by Region (2021-2026)
6.2 APAC PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
6.3 APAC PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PSMA Imaging Agent for Prostate Cancer by Country
7.1.1 Europe PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
7.1.2 Europe PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
7.2 Europe PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
7.3 Europe PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer by Country
8.1.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026)
8.3 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PSMA Imaging Agent for Prostate Cancer
10.3 Manufacturing Process Analysis of PSMA Imaging Agent for Prostate Cancer
10.4 Industry Chain Structure of PSMA Imaging Agent for Prostate Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PSMA Imaging Agent for Prostate Cancer Distributors
11.3 PSMA Imaging Agent for Prostate Cancer Customer
12 WORLD FORECAST REVIEW FOR PSMA IMAGING AGENT FOR PROSTATE CANCER BY GEOGRAPHIC REGION
12.1 Global PSMA Imaging Agent for Prostate Cancer Market Size Forecast by Region
12.1.1 Global PSMA Imaging Agent for Prostate Cancer Forecast by Region (2027-2032)
12.1.2 Global PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PSMA Imaging Agent for Prostate Cancer Forecast by Type (2027-2032)
12.7 Global PSMA Imaging Agent for Prostate Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus
13.1.1 Lantheus Company Information
13.1.2 Lantheus PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.1.3 Lantheus PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Main Business Overview
13.1.5 Lantheus Latest Developments
13.2 Telix Pharmaceuticals
13.2.1 Telix Pharmaceuticals Company Information
13.2.2 Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.2.3 Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Telix Pharmaceuticals Main Business Overview
13.2.5 Telix Pharmaceuticals Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.3.3 Novartis PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Blue Earth Diagnostics?Bracco?
13.4.1 Blue Earth Diagnostics?Bracco? Company Information
13.4.2 Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics?Bracco? Main Business Overview
13.4.5 Blue Earth Diagnostics?Bracco? Latest Developments
13.5 Sinotau
13.5.1 Sinotau Company Information
13.5.2 Sinotau PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.5.3 Sinotau PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinotau Main Business Overview
13.5.5 Sinotau Latest Developments
13.6 DC PHARMA
13.6.1 DC PHARMA Company Information
13.6.2 DC PHARMA PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.6.3 DC PHARMA PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 DC PHARMA Main Business Overview
13.6.5 DC PHARMA Latest Developments
13.7 Clarity Pharmaceuticals
13.7.1 Clarity Pharmaceuticals Company Information
13.7.2 Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.7.3 Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Clarity Pharmaceuticals Main Business Overview
13.7.5 Clarity Pharmaceuticals Latest Developments
13.8 Hengrui Pharma
13.8.1 Hengrui Pharma Company Information
13.8.2 Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.8.3 Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hengrui Pharma Main Business Overview
13.8.5 Hengrui Pharma Latest Developments
13.9 CRAND PHARMACEUTICAL
13.9.1 CRAND PHARMACEUTICAL Company Information
13.9.2 CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.9.3 CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CRAND PHARMACEUTICAL Main Business Overview
13.9.5 CRAND PHARMACEUTICAL Latest Developments
13.10 Norroy Bioscience
13.10.1 Norroy Bioscience Company Information
13.10.2 Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.10.3 Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Norroy Bioscience Main Business Overview
13.10.5 Norroy Bioscience Latest Developments
13.11 HUAYI RADIOPHARMACEUTICALS
13.11.1 HUAYI RADIOPHARMACEUTICALS Company Information
13.11.2 HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.11.3 HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 HUAYI RADIOPHARMACEUTICALS Main Business Overview
13.11.5 HUAYI RADIOPHARMACEUTICALS Latest Developments
13.12 Yunhe Pharma
13.12.1 Yunhe Pharma Company Information
13.12.2 Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.12.3 Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Yunhe Pharma Main Business Overview
13.12.5 Yunhe Pharma Latest Developments
13.13 C Ray Therapeutics
13.13.1 C Ray Therapeutics Company Information
13.13.2 C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.13.3 C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 C Ray Therapeutics Main Business Overview
13.13.5 C Ray Therapeutics Latest Developments
13.14 Curium Holding France S.A.S.
13.14.1 Curium Holding France S.A.S. Company Information
13.14.2 Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.14.3 Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Curium Holding France S.A.S. Main Business Overview
13.14.5 Curium Holding France S.A.S. Latest Developments
13.15 ABX advanced biochemical compounds GmbH
13.15.1 ABX advanced biochemical compounds GmbH Company Information
13.15.2 ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.15.3 ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 ABX advanced biochemical compounds GmbH Main Business Overview
13.15.5 ABX advanced biochemical compounds GmbH Latest Developments
13.16 Isotopia Molecular Imaging Ltd.
13.16.1 Isotopia Molecular Imaging Ltd. Company Information
13.16.2 Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
13.16.3 Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Isotopia Molecular Imaging Ltd. Main Business Overview
13.16.5 Isotopia Molecular Imaging Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PSMA Imaging Agent for Prostate Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PSMA Imaging Agent for Prostate Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 68Ga
Table 4. Major Players of 18F
Table 5. Global PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 6. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Table 7. Global PSMA Imaging Agent for Prostate Cancer Revenue by Type (2021-2026) & ($ million)
Table 8. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Type (2021-2026)
Table 9. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of First Generation
Table 11. Major Players of Second Generation
Table 12. Global PSMA Imaging Agent for Prostate Cancer Sales by Core Carrier Materials (2021-2026) & (K Units)
Table 13. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials (2021-2026)
Table 14. Global PSMA Imaging Agent for Prostate Cancer Revenue by Core Carrier Materials (2021-2026) & ($ million)
Table 15. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Core Carrier Materials (2021-2026)
Table 16. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Core Carrier Materials (2021-2026) & (US$/Unit)
Table 17. Major Players of Active Targeting
Table 18. Major Players of Passive Targeting
Table 19. Global PSMA Imaging Agent for Prostate Cancer Sales by Mechanism of Action (2021-2026) & (K Units)
Table 20. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action (2021-2026)
Table 21. Global PSMA Imaging Agent for Prostate Cancer Revenue by Mechanism of Action (2021-2026) & ($ million)
Table 22. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Mechanism of Action (2021-2026)
Table 23. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Mechanism of Action (2021-2026) & (US$/Unit)
Table 24. Global PSMA Imaging Agent for Prostate Cancer Sale by Application (2021-2026) & (K Units)
Table 25. Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2021-2026)
Table 26. Global PSMA Imaging Agent for Prostate Cancer Revenue by Application (2021-2026) & ($ million)
Table 27. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Application (2021-2026)
Table 28. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 29. Global PSMA Imaging Agent for Prostate Cancer Sales by Company (2021-2026) & (K Units)
Table 30. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company (2021-2026)
Table 31. Global PSMA Imaging Agent for Prostate Cancer Revenue by Company (2021-2026) & ($ millions)
Table 32. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company (2021-2026)
Table 33. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 34. Key Manufacturers PSMA Imaging Agent for Prostate Cancer Producing Area Distribution and Sales Area
Table 35. Players PSMA Imaging Agent for Prostate Cancer Products Offered
Table 36. PSMA Imaging Agent for Prostate Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Market M&A Activity & Strategy
Table 39. Global PSMA Imaging Agent for Prostate Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 40. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Geographic Region (2021-2026)
Table 41. Global PSMA Imaging Agent for Prostate Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 42. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 43. Global PSMA Imaging Agent for Prostate Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 44. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2021-2026)
Table 45. Global PSMA Imaging Agent for Prostate Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 46. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country/Region (2021-2026)
Table 47. Americas PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 48. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country (2021-2026)
Table 49. Americas PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026) & ($ millions)
Table 50. Americas PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 51. Americas PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 52. APAC PSMA Imaging Agent for Prostate Cancer Sales by Region (2021-2026) & (K Units)
Table 53. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Region (2021-2026)
Table 54. APAC PSMA Imaging Agent for Prostate Cancer Revenue by Region (2021-2026) & ($ millions)
Table 55. APAC PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 56. APAC PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 57. Europe PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 58. Europe PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026) & ($ millions)
Table 59. Europe PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 60. Europe PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 61. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 62. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Table 63. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 64. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of PSMA Imaging Agent for Prostate Cancer
Table 66. Key Market Challenges & Risks of PSMA Imaging Agent for Prostate Cancer
Table 67. Key Industry Trends of PSMA Imaging Agent for Prostate Cancer
Table 68. PSMA Imaging Agent for Prostate Cancer Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. PSMA Imaging Agent for Prostate Cancer Distributors List
Table 71. PSMA Imaging Agent for Prostate Cancer Customer List
Table 72. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 73. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Americas PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Americas PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. APAC PSMA Imaging Agent for Prostate Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 77. APAC PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Europe PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 79. Europe PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Type (2027-2032) & (K Units)
Table 83. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Type (2027-2032) & ($ millions)
Table 84. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 85. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 86. Lantheus Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 87. Lantheus PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 88. Lantheus PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Lantheus Main Business
Table 90. Lantheus Latest Developments
Table 91. Telix Pharmaceuticals Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 92. Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 93. Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Telix Pharmaceuticals Main Business
Table 95. Telix Pharmaceuticals Latest Developments
Table 96. Novartis Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 98. Novartis PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Blue Earth Diagnostics?Bracco? Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 102. Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 103. Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Blue Earth Diagnostics?Bracco? Main Business
Table 105. Blue Earth Diagnostics?Bracco? Latest Developments
Table 106. Sinotau Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 107. Sinotau PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 108. Sinotau PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Sinotau Main Business
Table 110. Sinotau Latest Developments
Table 111. DC PHARMA Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 112. DC PHARMA PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 113. DC PHARMA PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. DC PHARMA Main Business
Table 115. DC PHARMA Latest Developments
Table 116. Clarity Pharmaceuticals Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 117. Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 118. Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Clarity Pharmaceuticals Main Business
Table 120. Clarity Pharmaceuticals Latest Developments
Table 121. Hengrui Pharma Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 122. Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 123. Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Hengrui Pharma Main Business
Table 125. Hengrui Pharma Latest Developments
Table 126. CRAND PHARMACEUTICAL Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 127. CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 128. CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. CRAND PHARMACEUTICAL Main Business
Table 130. CRAND PHARMACEUTICAL Latest Developments
Table 131. Norroy Bioscience Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 132. Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 133. Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Norroy Bioscience Main Business
Table 135. Norroy Bioscience Latest Developments
Table 136. HUAYI RADIOPHARMACEUTICALS Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 137. HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 138. HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. HUAYI RADIOPHARMACEUTICALS Main Business
Table 140. HUAYI RADIOPHARMACEUTICALS Latest Developments
Table 141. Yunhe Pharma Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 142. Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 143. Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Yunhe Pharma Main Business
Table 145. Yunhe Pharma Latest Developments
Table 146. C Ray Therapeutics Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 147. C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 148. C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. C Ray Therapeutics Main Business
Table 150. C Ray Therapeutics Latest Developments
Table 151. Curium Holding France S.A.S. Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 152. Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 153. Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Curium Holding France S.A.S. Main Business
Table 155. Curium Holding France S.A.S. Latest Developments
Table 156. ABX advanced biochemical compounds GmbH Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 157. ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 158. ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. ABX advanced biochemical compounds GmbH Main Business
Table 160. ABX advanced biochemical compounds GmbH Latest Developments
Table 161. Isotopia Molecular Imaging Ltd. Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 162. Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 163. Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Isotopia Molecular Imaging Ltd. Main Business
Table 165. Isotopia Molecular Imaging Ltd. Latest Developments
Table 1. PSMA Imaging Agent for Prostate Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PSMA Imaging Agent for Prostate Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 68Ga
Table 4. Major Players of 18F
Table 5. Global PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 6. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Table 7. Global PSMA Imaging Agent for Prostate Cancer Revenue by Type (2021-2026) & ($ million)
Table 8. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Type (2021-2026)
Table 9. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of First Generation
Table 11. Major Players of Second Generation
Table 12. Global PSMA Imaging Agent for Prostate Cancer Sales by Core Carrier Materials (2021-2026) & (K Units)
Table 13. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials (2021-2026)
Table 14. Global PSMA Imaging Agent for Prostate Cancer Revenue by Core Carrier Materials (2021-2026) & ($ million)
Table 15. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Core Carrier Materials (2021-2026)
Table 16. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Core Carrier Materials (2021-2026) & (US$/Unit)
Table 17. Major Players of Active Targeting
Table 18. Major Players of Passive Targeting
Table 19. Global PSMA Imaging Agent for Prostate Cancer Sales by Mechanism of Action (2021-2026) & (K Units)
Table 20. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action (2021-2026)
Table 21. Global PSMA Imaging Agent for Prostate Cancer Revenue by Mechanism of Action (2021-2026) & ($ million)
Table 22. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Mechanism of Action (2021-2026)
Table 23. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Mechanism of Action (2021-2026) & (US$/Unit)
Table 24. Global PSMA Imaging Agent for Prostate Cancer Sale by Application (2021-2026) & (K Units)
Table 25. Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2021-2026)
Table 26. Global PSMA Imaging Agent for Prostate Cancer Revenue by Application (2021-2026) & ($ million)
Table 27. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Application (2021-2026)
Table 28. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 29. Global PSMA Imaging Agent for Prostate Cancer Sales by Company (2021-2026) & (K Units)
Table 30. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company (2021-2026)
Table 31. Global PSMA Imaging Agent for Prostate Cancer Revenue by Company (2021-2026) & ($ millions)
Table 32. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company (2021-2026)
Table 33. Global PSMA Imaging Agent for Prostate Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 34. Key Manufacturers PSMA Imaging Agent for Prostate Cancer Producing Area Distribution and Sales Area
Table 35. Players PSMA Imaging Agent for Prostate Cancer Products Offered
Table 36. PSMA Imaging Agent for Prostate Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Market M&A Activity & Strategy
Table 39. Global PSMA Imaging Agent for Prostate Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 40. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Geographic Region (2021-2026)
Table 41. Global PSMA Imaging Agent for Prostate Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 42. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 43. Global PSMA Imaging Agent for Prostate Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 44. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2021-2026)
Table 45. Global PSMA Imaging Agent for Prostate Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 46. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country/Region (2021-2026)
Table 47. Americas PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 48. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country (2021-2026)
Table 49. Americas PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026) & ($ millions)
Table 50. Americas PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 51. Americas PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 52. APAC PSMA Imaging Agent for Prostate Cancer Sales by Region (2021-2026) & (K Units)
Table 53. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Region (2021-2026)
Table 54. APAC PSMA Imaging Agent for Prostate Cancer Revenue by Region (2021-2026) & ($ millions)
Table 55. APAC PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 56. APAC PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 57. Europe PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 58. Europe PSMA Imaging Agent for Prostate Cancer Revenue by Country (2021-2026) & ($ millions)
Table 59. Europe PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 60. Europe PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 61. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Country (2021-2026) & (K Units)
Table 62. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Table 63. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Type (2021-2026) & (K Units)
Table 64. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales by Application (2021-2026) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of PSMA Imaging Agent for Prostate Cancer
Table 66. Key Market Challenges & Risks of PSMA Imaging Agent for Prostate Cancer
Table 67. Key Industry Trends of PSMA Imaging Agent for Prostate Cancer
Table 68. PSMA Imaging Agent for Prostate Cancer Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. PSMA Imaging Agent for Prostate Cancer Distributors List
Table 71. PSMA Imaging Agent for Prostate Cancer Customer List
Table 72. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 73. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Americas PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Americas PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. APAC PSMA Imaging Agent for Prostate Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 77. APAC PSMA Imaging Agent for Prostate Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Europe PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 79. Europe PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Type (2027-2032) & (K Units)
Table 83. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Type (2027-2032) & ($ millions)
Table 84. Global PSMA Imaging Agent for Prostate Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 85. Global PSMA Imaging Agent for Prostate Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 86. Lantheus Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 87. Lantheus PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 88. Lantheus PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Lantheus Main Business
Table 90. Lantheus Latest Developments
Table 91. Telix Pharmaceuticals Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 92. Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 93. Telix Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Telix Pharmaceuticals Main Business
Table 95. Telix Pharmaceuticals Latest Developments
Table 96. Novartis Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 98. Novartis PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Blue Earth Diagnostics?Bracco? Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 102. Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 103. Blue Earth Diagnostics?Bracco? PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Blue Earth Diagnostics?Bracco? Main Business
Table 105. Blue Earth Diagnostics?Bracco? Latest Developments
Table 106. Sinotau Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 107. Sinotau PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 108. Sinotau PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Sinotau Main Business
Table 110. Sinotau Latest Developments
Table 111. DC PHARMA Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 112. DC PHARMA PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 113. DC PHARMA PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. DC PHARMA Main Business
Table 115. DC PHARMA Latest Developments
Table 116. Clarity Pharmaceuticals Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 117. Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 118. Clarity Pharmaceuticals PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Clarity Pharmaceuticals Main Business
Table 120. Clarity Pharmaceuticals Latest Developments
Table 121. Hengrui Pharma Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 122. Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 123. Hengrui Pharma PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Hengrui Pharma Main Business
Table 125. Hengrui Pharma Latest Developments
Table 126. CRAND PHARMACEUTICAL Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 127. CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 128. CRAND PHARMACEUTICAL PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. CRAND PHARMACEUTICAL Main Business
Table 130. CRAND PHARMACEUTICAL Latest Developments
Table 131. Norroy Bioscience Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 132. Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 133. Norroy Bioscience PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Norroy Bioscience Main Business
Table 135. Norroy Bioscience Latest Developments
Table 136. HUAYI RADIOPHARMACEUTICALS Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 137. HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 138. HUAYI RADIOPHARMACEUTICALS PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. HUAYI RADIOPHARMACEUTICALS Main Business
Table 140. HUAYI RADIOPHARMACEUTICALS Latest Developments
Table 141. Yunhe Pharma Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 142. Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 143. Yunhe Pharma PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Yunhe Pharma Main Business
Table 145. Yunhe Pharma Latest Developments
Table 146. C Ray Therapeutics Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 147. C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 148. C Ray Therapeutics PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. C Ray Therapeutics Main Business
Table 150. C Ray Therapeutics Latest Developments
Table 151. Curium Holding France S.A.S. Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 152. Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 153. Curium Holding France S.A.S. PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Curium Holding France S.A.S. Main Business
Table 155. Curium Holding France S.A.S. Latest Developments
Table 156. ABX advanced biochemical compounds GmbH Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 157. ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 158. ABX advanced biochemical compounds GmbH PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. ABX advanced biochemical compounds GmbH Main Business
Table 160. ABX advanced biochemical compounds GmbH Latest Developments
Table 161. Isotopia Molecular Imaging Ltd. Basic Information, PSMA Imaging Agent for Prostate Cancer Manufacturing Base, Sales Area and Its Competitors
Table 162. Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Product Portfolios and Specifications
Table 163. Isotopia Molecular Imaging Ltd. PSMA Imaging Agent for Prostate Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Isotopia Molecular Imaging Ltd. Main Business
Table 165. Isotopia Molecular Imaging Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of PSMA Imaging Agent for Prostate Cancer
Figure 2. PSMA Imaging Agent for Prostate Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PSMA Imaging Agent for Prostate Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PSMA Imaging Agent for Prostate Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PSMA Imaging Agent for Prostate Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2025)
Figure 10. PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 68Ga
Figure 12. Product Picture of 18F
Figure 13. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type in 2026
Figure 14. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of First Generation
Figure 16. Product Picture of Second Generation
Figure 17. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials in 2026
Figure 18. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Core Carrier Materials (2021-2026)
Figure 19. Product Picture of Active Targeting
Figure 20. Product Picture of Passive Targeting
Figure 21. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action in 2026
Figure 22. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Mechanism of Action (2021-2026)
Figure 23. PSMA Imaging Agent for Prostate Cancer Consumed in Nuclear Medicine and Molecular Imaging
Figure 24. Global PSMA Imaging Agent for Prostate Cancer Market: Nuclear Medicine and Molecular Imaging (2021-2026) & (K Units)
Figure 25. PSMA Imaging Agent for Prostate Cancer Consumed in Precision Oncology Diagnostics
Figure 26. Global PSMA Imaging Agent for Prostate Cancer Market: Precision Oncology Diagnostics (2021-2026) & (K Units)
Figure 27. PSMA Imaging Agent for Prostate Cancer Consumed in Radiopharmaceuticals and Radiopharmaceuticals
Figure 28. Global PSMA Imaging Agent for Prostate Cancer Market: Radiopharmaceuticals and Radiopharmaceuticals (2021-2026) & (K Units)
Figure 29. Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2025)
Figure 30. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Application in 2025
Figure 31. PSMA Imaging Agent for Prostate Cancer Sales by Company in 2025 (K Units)
Figure 32. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company in 2025
Figure 33. PSMA Imaging Agent for Prostate Cancer Revenue by Company in 2025 ($ millions)
Figure 34. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company in 2025
Figure 35. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Geographic Region in 2025
Figure 37. Americas PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 38. Americas PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 39. APAC PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 40. APAC PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 41. Europe PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 42. Europe PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 45. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country in 2025
Figure 46. Americas PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Figure 47. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 48. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 49. United States PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Region in 2025
Figure 54. APAC PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Region (2021-2026)
Figure 55. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 56. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 57. China PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 61. India PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country in 2025
Figure 65. Europe PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Figure 66. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 67. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 68. Germany PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 69. France PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 70. UK PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 76. Egypt PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of PSMA Imaging Agent for Prostate Cancer in 2026
Figure 82. Manufacturing Process Analysis of PSMA Imaging Agent for Prostate Cancer
Figure 83. Industry Chain Structure of PSMA Imaging Agent for Prostate Cancer
Figure 84. Channels of Distribution
Figure 85. Global PSMA Imaging Agent for Prostate Cancer Sales Market Forecast by Region (2027-2032)
Figure 86. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of PSMA Imaging Agent for Prostate Cancer
Figure 2. PSMA Imaging Agent for Prostate Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PSMA Imaging Agent for Prostate Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PSMA Imaging Agent for Prostate Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PSMA Imaging Agent for Prostate Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2025)
Figure 10. PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 68Ga
Figure 12. Product Picture of 18F
Figure 13. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type in 2026
Figure 14. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of First Generation
Figure 16. Product Picture of Second Generation
Figure 17. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Core Carrier Materials in 2026
Figure 18. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Core Carrier Materials (2021-2026)
Figure 19. Product Picture of Active Targeting
Figure 20. Product Picture of Passive Targeting
Figure 21. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Mechanism of Action in 2026
Figure 22. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Mechanism of Action (2021-2026)
Figure 23. PSMA Imaging Agent for Prostate Cancer Consumed in Nuclear Medicine and Molecular Imaging
Figure 24. Global PSMA Imaging Agent for Prostate Cancer Market: Nuclear Medicine and Molecular Imaging (2021-2026) & (K Units)
Figure 25. PSMA Imaging Agent for Prostate Cancer Consumed in Precision Oncology Diagnostics
Figure 26. Global PSMA Imaging Agent for Prostate Cancer Market: Precision Oncology Diagnostics (2021-2026) & (K Units)
Figure 27. PSMA Imaging Agent for Prostate Cancer Consumed in Radiopharmaceuticals and Radiopharmaceuticals
Figure 28. Global PSMA Imaging Agent for Prostate Cancer Market: Radiopharmaceuticals and Radiopharmaceuticals (2021-2026) & (K Units)
Figure 29. Global PSMA Imaging Agent for Prostate Cancer Sale Market Share by Application (2025)
Figure 30. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Application in 2025
Figure 31. PSMA Imaging Agent for Prostate Cancer Sales by Company in 2025 (K Units)
Figure 32. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Company in 2025
Figure 33. PSMA Imaging Agent for Prostate Cancer Revenue by Company in 2025 ($ millions)
Figure 34. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Company in 2025
Figure 35. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Geographic Region in 2025
Figure 37. Americas PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 38. Americas PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 39. APAC PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 40. APAC PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 41. Europe PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 42. Europe PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Revenue 2021-2026 ($ millions)
Figure 45. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country in 2025
Figure 46. Americas PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Figure 47. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 48. Americas PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 49. United States PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Region in 2025
Figure 54. APAC PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Region (2021-2026)
Figure 55. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 56. APAC PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 57. China PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 61. India PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country in 2025
Figure 65. Europe PSMA Imaging Agent for Prostate Cancer Revenue Market Share by Country (2021-2026)
Figure 66. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 67. Europe PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 68. Germany PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 69. France PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 70. UK PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Market Share by Application (2021-2026)
Figure 76. Egypt PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries PSMA Imaging Agent for Prostate Cancer Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of PSMA Imaging Agent for Prostate Cancer in 2026
Figure 82. Manufacturing Process Analysis of PSMA Imaging Agent for Prostate Cancer
Figure 83. Industry Chain Structure of PSMA Imaging Agent for Prostate Cancer
Figure 84. Channels of Distribution
Figure 85. Global PSMA Imaging Agent for Prostate Cancer Sales Market Forecast by Region (2027-2032)
Figure 86. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global PSMA Imaging Agent for Prostate Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global PSMA Imaging Agent for Prostate Cancer Revenue Market Share Forecast by Application (2027-2032)
